BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 18, 2007
View Archived Issues
PARP inhibition may be beneficial in retinitis pigmentosa / News in Context
Read More
Latest findings reported for therapeutic agents under development for treatment of plaque psoriasis
Read More
Preclinical data on two novel PPAR modulators from Pierre Fabre
Read More
Inhibition of integrin alpha5beta1 may be useful in treating ocular neovascularization
Read More
Alizyme provides update on phase III programs
Read More
Novacea initiates phase II trial with AQ4N for ALL
Read More
BioCryst begins patient enrollment in pivotal forodesine trial
Read More
Threshold stops enrollment in phase II trial of glufosfamide
Read More
MedImmune and Crucell develop new antibodies for hospital-acquired bacterial infection
Read More
Neuron and Metabolic select NRP compound with therapeutic potential
Read More
Promising phase II data reported from ASA-404 phase II trial
Read More
Sanofi Pasteur and Institut Pasteur to codevelop malaria vaccine
Read More
AMDL seeks FDA approval for ELISA tumor marker test
Read More
Novel treatment option for drug addiction disclosed by State University of New York
Read More
Orexo to acquire Biolipox
Read More
Bristol-Myers Squibb licenses SARM program to Pharmacopeia
Read More
Disappointing phase II data reported for MEM-1003
Read More
Expansion cohort in phase I Hedgehog antagonist trial initiated by Genentech
Read More
FDA approves IND for CA9-SCAN pivotal phase III trial
Read More
FDA grants orphan drug status for tamibarotene in acute promyelocytic leukemia
Read More
Neuromed concludes SPA with FDA for a pivotal phase III NMED-1077 trial
Read More
Wyeth and Progenics initiate phase II oral methylnaltrexone trials
Read More
Pivotal phase III Zingo trial meets primary endpoint
Read More
Novel class I HDAC inhibitor developed at Merck & Co.
Read More
Recent patents disclose novel anxiolytic, antidepressant and antipsychotic agents
Read More
Only FDA-approved anthracycline extravasation kit reaches market
Read More
Study suggests feasibility of vaccine prevention of maternal CMV infection
Read More
Recent Bayer Schering Pharma patents report novel agents for male contraception
Read More